Who Gets Prescriptions for Proton Pump Inhibitors and Why? A Drug-utilization Study with Claims Data in Bavaria, Germany, 2010-2018

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2021 Dec 8

PMID 34877614

Citations 13

Authors

Ina-Maria Ruckert-Eheberg

Michael Nolde

Nayeon Ahn

Martin Tauscher

Roman Gerlach

Florian Guntner

Alexander Gunter

Christa Meisinger

Jakob Linseisen

Ute Amann

Sebastian-Edgar Baumeister

Affiliations

Soon will be listed here.

Abstract

Purpose: The German annual drug prescription-report has indicated overuse of proton pump inhibitors (PPIs) for many years; however, little was known about the characteristics of people using PPIs. This study aimed to provide comprehensive utilization data and describe frequencies of potential on- and off-label PPI-indications in Bavaria, Germany.

Methods: Claims data of statutorily insured people from 2010 to 2018 were used. Defined daily doses (DDDs) of PPIs by type of drug, prevalence of PPI-use and DDDs prescribed per 1000 insured people/day were analyzed. For 2018, proportions of users and DDDs per 1000 insured people were calculated by age and sex. To elucidate changes in prescribing practices due to a suspected drug-drug interaction, we examined co-prescribing of clopidogrel and PPIs between 2010 and 2018. For PPI new users, sums of DDDs and frequencies of potential indications were examined.

Results: PPI prescribing increased linearly from 2010 to 2016 and gradually decreased from 2016 to 2018. In 2018, 14.7% of women and 12.2% of men received at least one prescription, and 64.8 DDDs (WHO-def.) per 1000 insured people/day were prescribed. Overall, omeprazole use decreased over the observation period and was steadily replaced by pantoprazole, especially when co-prescibed with clopidogrel. An on-label PPI-indication was not reported at first intake in 52.0% of new users.

Conclusions: The utilization of prescribed PPIs has decreased since 2016. However, a large proportion of new PPI-users had no documentation of a potential indication, and the sums of DDDs prescribed often seemed not to comply with guidelines.

Citing Articles

Utilization of Acid Suppressants After Withdrawal of Ranitidine in Korea: An Interrupted Time Series Analysis.

Choi J, Kim S, Park J, Kim M, Choi N, Shin C J Prev Med Public Health. 2025; 58(1):21-30.

PMID: 39788691 PMC: 11824620. DOI: 10.3961/jpmph.24.357.

Proton pump inhibitors in inpatients: Are we getting it right? A retrospective analysis.

Karuppasamy G, Yahia Y, Parambil J, Ismail S, Danjuma M Qatar Med J. 2024; 2024(4):60.

PMID: 39552948 PMC: 11568192. DOI: 10.5339/qmj.2024.60.

Are integrated care models associated with improved drug safety in Swiss primary care? an observational analysis using healthcare claims data.

Farcher R, Graber S, Boes S, Huber C PLoS One. 2024; 19(9):e0311099.

PMID: 39325745 PMC: 11426503. DOI: 10.1371/journal.pone.0311099.

Proton Pump Inhibitor Prescription in Nursing Home Residents: Prevalence, Appropriateness, and Associated Factors-A Secondary Data Analysis from Three German Regions and the Impact of Guideline Recommendations.

Wolf U, Wegener M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204187 PMC: 11360722. DOI: 10.3390/ph17081082.

Gentamicin combination treatment is associated with lower mortality in patients with invasive listeriosis: a retrospective analysis.

Sutter J, Kocheise L, Kempski J, Christner M, Wichmann D, Pinnschmidt H Infection. 2024; 52(4):1601-1606.

PMID: 38963609 PMC: 11289180. DOI: 10.1007/s15010-024-02330-w.

References

Malfertheiner P, Kandulski A, Venerito M . Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017; 14(12):697-710. DOI: 10.1038/nrgastro.2017.117. View

Gotz M, Anders M, Biecker E, Bojarski C, Braun G, Brechmann T . [S2k Guideline Gastrointestinal Bleeding - Guideline of the German Society of Gastroenterology DGVS]. Z Gastroenterol. 2017; 55(9):883-936. DOI: 10.1055/s-0043-116856. View

Norgard N, Mathews K, Wall G . Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009; 43(7):1266-74. DOI: 10.1345/aph.1M051. View

Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid F . Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017; 63(5):354-364. PMC: 5429051. View

Bytzer P . Deprescribing proton pump inhibitors: why, when and how. Med J Aust. 2018; 209(10):436-438. DOI: 10.5694/mja18.00674. View

Rieckert A, Becker A, Donner-Banzhof N, Viniol A, Bucker B, Wilm S . Reduction of the long-term use of proton pump inhibitors by a patient-oriented electronic decision support tool (arriba-PPI): study protocol for a randomized controlled trial. Trials. 2019; 20(1):636. PMC: 6868794. DOI: 10.1186/s13063-019-3728-2. View

Matuz M, Benko R, Engi Z, Schvab K, Doro P, Viola R . Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol. 2020; 11:552102. PMC: 7506043. DOI: 10.3389/fphar.2020.552102. View

Haastrup P, Paulsen M, Christensen R, Sondergaard J, Hansen J, Jarbol D . Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther. 2016; 44(1):78-87. DOI: 10.1111/apt.13649. View

Naunton M, Peterson G, Deeks L, Young H, Kosari S . We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther. 2017; 43(1):65-72. DOI: 10.1111/jcpt.12613. View

10.

Sakata Y, Tsuruoka N, Takedomi H, Akutagawa T, Shimoda R, Esaki M . A Study on the Status of Proton Pump Inhibitor Prescriptions Using Diagnosis Procedure Combination Data in Japan. Digestion. 2019; 101(3):308-315. DOI: 10.1159/000498967. View

11.

Helgadottir H, Bjornsson E . Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci. 2019; 20(21). PMC: 6862638. DOI: 10.3390/ijms20215469. View

12.

Thomson A . Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep. 2000; 2(6):482-93. DOI: 10.1007/s11894-000-0013-0. View

13.

Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S . [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. Z Gastroenterol. 2016; 54(4):327-63. DOI: 10.1055/s-0042-102967. View

14.

Forgerini M, Mieli S, Mastroianni P . Safety assessment of omeprazole use: a review. Sao Paulo Med J. 2019; 136(6):557-570. PMC: 9897136. DOI: 10.1590/1516-3180.2018.0019220318. View

15.

Fischbach W . [Drug-induced gastrointestinal bleeding]. Internist (Berl). 2019; 60(6):597-607. DOI: 10.1007/s00108-019-0610-y. View

16.

Pottegard A, Broe A, Hallas J, de Muckadell O, Lassen A, Lodrup A . Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol. 2016; 9(5):671-8. PMC: 4984329. DOI: 10.1177/1756283X16650156. View

17.

Hollingworth S, Duncan E, Martin J . Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010; 19(10):1019-24. DOI: 10.1002/pds.1969. View

18.

Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F . Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol. 2019; 76(3):449-457. DOI: 10.1007/s00228-019-02810-1. View

19.

Hoffmann F, Glaeske G, Schmiemann G . [Increased prescribing of proton pump inhibitors in ambulatory care over the years 2005 - 2013]. Z Gastroenterol. 2014; 53(2):95-100. DOI: 10.1055/s-0034-1384973. View

20.

Tett S, Sketris I, Cooke C, Veldhuyzen Van Zanten S, Barozzi N . Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada. Pharmacoepidemiol Drug Saf. 2013; 22(7):735-43. DOI: 10.1002/pds.3442. View